Oncologic PET/CT: current status and controversies.
The introduction of integrated PET/CT has dramatically increased the worldwide rate of growth for PET, predominantly for oncologic imaging with the glucose analog 18F-fluorodeoxyglucose (FDG). A rapidly expanding body of literature demonstrates that the use of FDG-PET/CT and the resultant ability to interpret coregistered and fused PET and CT images lead to improved observer confidence and improved diagnostic performance by comparison with PET alone, CT alone, and visually correlated PET and CT. The value of PET/CT is likely to be even greater with new PET radiopharmaceuticals under development, many of which produce PET images with even fewer anatomical landmarks than FDG images. PET/CT is also likely to lead to the resurrection of 18F-fluoride as a principal agent for radionuclide bone imaging. There are a number of controversies related to PET/CT, including minimum training and experience requirements for interpreting physicians and defining new models for technical and professional reimbursement.
Siegel
Barry A
BA
Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA. siegelb@mir.wustl.edu
Dehdashti
Farrokh
F
D002983:Clinical Competence; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging*; D009683:Nuclear Medicine / Q000193:education; D049268:Positron-Emission Tomography / Q000191:economics / Q000379:methods*; D011859:Radiography; D011871:Radiology / Q000193:education; D019275:Radiopharmaceuticals; D012984:Software; D014055:Tomography, Emission-Computed / Q000191:economics / Q000379:methods*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18